13F filer · CIK 1583977
Cormorant Asset Management, LP
BOSTON, MA · filing since Q4 2013 · last filing Aug 14, 2026
Reported value
$2.0B
$-39.6M vs prior
Positions
50
New / sold out
13 / 10
Added / reduced
4 / 28
Turnover
14.2%
buys $279.6M · sells $558.1M
Top-10 weight
59.2%
Biggest buys vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| New | PARABILIS MEDICINES INC | +4,615,612 | – | +$126.3M |
| New | CLIMB BIO INC | +2,106,000 | – | +$27.5M |
| New | SPYRE THERAPEUTICS INC | +225,000 | – | +$20.0M |
| New | DEFINIUM THERAPEUTICS INC | +400,000 | – | +$18.8M |
| New | ASCENDIS PHARMA A/S | +50,000 | – | +$13.3M |
| Added | BIOHAVEN LTD | +850,000 | +48.3% | +$12.6M |
| Added | ADLAI NORTYE LTD | +1,080,372 | +37.3% | +$12.4M |
| New | KAILERA THERAPEUTICS INC | +550,000 | – | +$12.1M |
| New | ENLIVEN THERAPEUTICS INC | +150,000 | – | +$7.6M |
| New | IBIO INC | +3,570,000 | – | +$6.2M |
7 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Biggest sells vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Reduced | PRAXIS PRECISION MEDICINES I | -245,500 | -27.7% | $-82.2M |
| Sold out | CENTESSA PHARMACEUTICALS PLC | -1,050,000 | -100.0% | $-41.7M |
| Reduced | MBX BIOSCIENCES INC | -570,000 | -50.9% | $-31.5M |
| Reduced | EDGEWISE THERAPEUTICS INC | -750,000 | -23.0% | $-30.5M |
| Reduced | MOONLAKE IMMUNOTHERAPEUTICS | -1,275,000 | -28.5% | $-24.8M |
| Sold out | MAZE THERAPEUTICS INC | -750,000 | -100.0% | $-22.4M |
| Reduced | BRIDGEBIO PHARMA INC | -300,000 | -35.3% | $-22.3M |
| Reduced | OLEMA PHARMACEUTICALS INC | -1,750,000 | -44.9% | $-21.9M |
| Sold out | ASCENDIS PHARMA A/S | -95,000 | -100.0% | $-21.7M |
| Reduced | DIANTHUS THERAPEUTICS INC | -200,000 | -21.1% | $-19.5M |
28 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q2 2026
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | PRAXIS PRECISION MEDICINES ICOM NEW | 640,000 | $214.3M | 10.98% |
| 2 | BRIDGEBIO ONCOLOGY THERAPEUTCOM NEW | 17,878,594 | $136.2M | 6.98% |
| 3 | PARABILIS MEDICINES INCCOM | 4,615,612 | $126.3M | 6.47% |
| 4 | RAPPORT THERAPEUTICS INCCOM | 2,657,521 | $110.7M | 5.67% |
| 5 | ERASCA INCCOM | 6,000,000 | $109.9M | 5.63% |
| 6 | EDGEWISE THERAPEUTICS INCCOM | 2,510,000 | $102.0M | 5.23% |
| 7 | EYEPOINT INCCOM NEW | 7,000,000 | $100.1M | 5.13% |
| 8 | ALUMIS INCCOM | 3,285,596 | $92.5M | 4.74% |
| 9 | ABIVAX SASPONSORED ADS | 675,000 | $90.0M | 4.61% |
| 10 | DIANTHUS THERAPEUTICS INCCOM | 750,000 | $73.1M | 3.75% |
40 more rows. Subscribe for $29/month to see every row, download the data and use the API.